cyclophosphamide + epirubicin + gemcitabine + paclitaxel + trastuzumab

This is a combination chemotherapy regimen that includes multiple anticancer agents with different mechanisms of action. The combination includes: - Cyclophosphamide: An alkylating agent that works by damaging DNA and preventing cancer cell replication - Epirubicin: An anthracycline antibiotic that intercalates with DNA and inhibits topoisomerase II - Gemcitabine: A nucleoside analog that inhibits DNA synthesis - Paclitaxel: A taxane that stabilizes microtubules, preventing cell division - Trastuzumab (Herceptin): A monoclonal antibody that targets HER2 receptors This combination is likely used for HER2-positive breast cancer treatment, as trastuzumab specifically targets the HER2 protein overexpressed in certain breast cancers.